204 results on '"Panchia, Ravindre"'
Search Results
2. Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization
- Author
-
Liu, Gui, Mugo, Nelly R, Brown, Elizabeth R, Mgodi, Nyaradzo M, Chirenje, Zvavahera M, Marrazzo, Jeanne M, Winer, Rachel L, Mansoor, Leila, Palanee-Phillips, Thesla, Siva, Samantha S, Naidoo, Logashvari, Jeenarain, Nitesha, Gaffoor, Zakir, Nair, Gonasagrie L, Selepe, Pearl, Nakabiito, Clemensia, Mkhize, Baningi, Mirembe, Brenda Gati, Taljaard, Marthinette, Panchia, Ravindre, Baeten, Jared M, Balkus, Jennifer E, Hladik, Florian, Celum, Connie L, and Barnabas, Ruanne V
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Sexually Transmitted Infections ,Infectious Diseases ,Cancer ,Cervical Cancer ,Prevention ,Immunization ,HIV/AIDS ,Adolescent Sexual Activity ,Clinical Research ,HPV and/or Cervical Cancer Vaccines ,Vaccine Related ,Pediatric ,Prevention of disease and conditions ,and promotion of well-being ,3.4 Vaccines ,Infection ,Good Health and Well Being ,Adult ,Alphapapillomavirus ,Case-Control Studies ,Female ,HIV Infections ,Humans ,Papillomaviridae ,Papillomavirus Infections ,Papillomavirus Vaccines ,Prevalence ,Risk Factors ,Vaccination ,Young Adult ,adolescent girls and young women ,cervical cancer ,HIV acquisition ,human papillomavirus ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Virology ,Biomedical and clinical sciences ,Health sciences - Abstract
ObjectiveVaccine-preventable human papillomavirus (HPV) infection is common, especially in sub-Saharan Africa where HIV risk is also high. However, unlike other sexually transmitted infections (STIs), HPV's role in HIV acquisition is unclear. We evaluated this relationship using data from MTN-003, a clinical trial of HIV chemoprophylaxis among cisgender women in sub-Saharan Africa.DesignA case-control study.MethodsWe matched 138 women who acquired HIV (cases) to 412 HIV-negative controls. Cervicovaginal swabs collected within 6 months before HIV seroconversion were tested for HPV DNA. We estimated the associations between carcinogenic (high-risk) and low-risk HPV types and types targeted by HPV vaccines and HIV acquisition, using conditional logistic regression models adjusted for time-varying sexual behaviors and other STIs.ResultsMean age was 23 (±4) years. Any, high-risk and low-risk HPV was detected in 84, 74 and 66% of cases, and 65, 55 and 48% of controls. Infection with at least two HPV types was common in cases (67%) and controls (49%), as was infection with nonavalent vaccine-targeted types (60 and 42%). HIV acquisition increased with any [adjusted odds ratio (aOR) 2.5, 95% confidence interval (95% CI) 1.3-4.7], high-risk (aOR 2.6, 95% CI 1.5-4.6) and low-risk (aOR 1.8, 95% CI 1.1-2.9) HPV. Each additional type detected increased HIV risk by 20% (aOR 1.2, 95% CI 1.1-1.4). HIV acquisition was associated with HPV types targeted by the nonavalent (aOR 2.1, 95% CI 1.3-3.6) and quadrivalent vaccines (aOR 1.9, 95% CI 1.1-3.2).ConclusionHPV infection is associated with HIV acquisition in sub-Saharan African women. In addition to preventing HPV-associated cancers, increasing HPV vaccination coverage could potentially reduce HIV incidence.
- Published
- 2022
3. Correction to “Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study”
- Author
-
Seneviratne, Herana Kamal, Hamlin, Allyson N, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Kuo, Irene, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R, McCauley, Marybeth, Eron, Joseph J, Cohen, Myron S, Landovitz, Raphael J, Hendrix, Craig W, and Bumpus, Namandjé N
- Abstract
[This corrects the article DOI: 10.1021/acsptsci.0c00181.].
- Published
- 2021
4. Prevalence and Incidence of Sexually Transmitted Infection in Injectable Progestin Contraception Users in South Africa
- Author
-
Noguchi, Lisa M, Marrazzo, Jeanne M, Richardson, Barbara, Hillier, Sharon L, Balkus, Jennifer E, Palanee-Phillips, Thesla, Nair, Gonasagrie, Panchia, Ravindre, Piper, Jeanna, Gomez, Kailazarid, Ramjee, Gita, and Chirenje, Z Mike
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Clinical Trials and Supportive Activities ,Sexually Transmitted Infections ,Prevention ,HIV/AIDS ,Infectious Diseases ,Infection ,Good Health and Well Being ,depot medroxyprogesterone acetate ,norethisterone enanthate ,chlamydia ,gonorrhea ,contraception ,trichomoniasis ,syphilis ,HSV-2 - Abstract
IntroductionWhether intramuscular depot medroxyprogesterone acetate (DMPA-IM) and norethisterone enanthate (NET-EN) have a differential impact on the incidence of sexually transmitted infection (STI) remains unclear. In the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial, HIV-1 acquisition was higher for DMPA-IM users vs. NET-EN users. We compared DMPA-IM and NET-EN users with regard to chlamydia, gonorrhea, trichomoniasis, syphilis, and herpes simplex virus type 2 (HSV-2) infection.Materials and methodsProspective data were analyzed from VOICE, a randomized trial of HIV-1 chemoprophylaxis. Participants were evaluated annually and as indicated for chlamydia, gonorrhea, trichomoniasis, and syphilis. Stored specimens were tested for HSV-2. Proportional hazards models compared the risk of STI between DMPA-IM and NET-EN users.ResultsAmong 2,911 injectable contraception users in South Africa, 1,800 (61.8%) used DMPA-IM and 1,111 used NET-EN (38.2%). DMPA-IM and NET-EN users did not differ in baseline chlamydia: 15.1 vs. 14.3%, p= 0.54; gonorrhea: 3.4 vs. 3.7%, p= 0.70; trichomoniasis: 5.7 vs.5.0%, p= 0.40; or syphilis: 1.5 vs. 0.7%, p= 0.08; but differed for baseline HSV-2: (51.3 vs. 38.6%, p < 0.001). Four hundred forty-eight incident chlamydia, 103 gonorrhea, 150 trichomonas, 17 syphilis, and 48 HSV-2 infections were detected over 2,742, 2,742, 2,783, 2,945, and 756 person-years (py), respectively (chlamydia 16.3/100 py; gonorrhea 3.8/100 py; trichomoniasis 5.4/100 py; syphilis 0.6/100 py; HSV-2 6.4/100 py). Comparing DMPA-IM with NET-EN users, no difference was noted in the incidence of chlamydia, gonorrhea, trichomoniasis, syphilis, or HSV2 infections, including when adjusted for confounders [chlamydia (aHR 1.03, 95% CI 0.85-1.25), gonorrhea (aHR 0.88, 95% CI 0.60-1.31), trichomoniasis (aHR 1.07, 95% CI 0.74-1.54), syphilis (aHR 0.41, 95% CI 0.15-1.10), and HSV-2 (aHR 0.83, 95% CI 0.45-1.54, p= 0.56)].DiscussionAmong South African participants enrolled in VOICE, DMPA-IM and NETEN users differed in prevalence of HSV-2 at baseline but did not differ in the incidence of chlamydia, gonorrhea, trichomoniasis, syphilis, or HSV-2 infection. Differential HIV-1 acquisition, previously demonstrated in this cohort, does not appear to be explained by differential STI acquisition. However, the high incidence of multiple STIs reinforces the need to accelerate access to comprehensive sexual and reproductive health services.
- Published
- 2021
5. Likely clinical depression and HIV-related decline in antiretroviral therapy untreated women who seroconverted during participation in microbicide trials in sub-Saharan Africa
- Author
-
Rael, Christine T, Roberts, Sarah, Ibitoye, Mbolaji, Gorbach, Pamina M, Palanee-Phillips, Thesla, Harkoo, Ishana, Mbilizi, Yamikani, Panchia, Ravindre, Siva, Samantha, Tembo, Tchangani, Akello, Carolyne Agwau, Balkus, Jennifer, Riddler, Sharon, and Carballo-Diéguez, Alex
- Subjects
Infectious Diseases ,HIV/AIDS ,Clinical Research ,Behavioral and Social Science ,Depression ,Clinical Trials and Supportive Activities ,Brain Disorders ,Mental Health ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Infection ,Good Health and Well Being ,Anti-HIV Agents ,Anti-Infective Agents ,Cross-Sectional Studies ,Female ,HIV Infections ,Humans ,Male ,Viral Load ,Clinical Sciences ,Medical Microbiology ,Public Health and Health Services ,Public Health - Abstract
Depression worsens HIV outcomes in populations treated with antiretroviral therapy (ART) medications. Data are limited on the relationship between depression and HIV in untreated populations in sub-Saharan Africa. We aimed to identify associations between likely clinical depression, alcohol use, social support by partners, and HIV viral load (VL) among ART untreated women who recently became HIV positive and enrolled in the Microbicide Trials Network (MTN)-015 study. Analyses used cross-sectional data collected at baseline in MTN-015. Participants in this analysis (N = 190) enrolled from other MTN trials were not receiving ART and provided data on their HIV disclosure status to their husband or male partner and alcohol use behavior. The dependent variable, VL, was categorized as: low (≤400 RNA copies/mL; 9.1% of participants), medium (401-20,000 RNA copies/mL; 48.8%), and high (>20,000 RNA copies/mL; 42.0%). Depression was assessed using eight items from Hopkins Symptom Checklist; a cutoff of ≥1.75 indicated likely clinical depression. Independent variables with a significance of p ≤ 0.05 in unadjusted regressions were included in a regression adjusted for age, education, and time since seroconversion. Depressive symptoms were positively associated with high VL, in the adjusted regression (OR = 1.80; 95% CI = 1.07-3.01). Results suggest that likely having clinical depression may have a biological relationship with HIV disease progression.
- Published
- 2021
6. Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study
- Author
-
Seneviratne, Herana Kamal, Hamlin, Allyson N, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Kuo, Irene, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Adeyeye, Adeola, Rinehart, Alex R, McCauley, Marybeth, Eron, Joseph S, Cohen, Myron S, Landovitz, Raphael J, Hendrix, Craig W, and Bumpus, Namandjé N
- Subjects
Prevention ,Biotechnology ,Genetics ,Human Genome ,cabotegravir ,long-acting ,human immunodeficiency virus ,pre-exposure prophylaxis ,uridine diphosphate glucuronosyltransferase ,cabotegravir-glucuronide - Abstract
Cabotegravir (CAB) is an integrase strand-transfer inhibitor of HIV that has proven effective for HIV treatment and prevention in a long-acting injectable formulation, typically preceded by an oral formulation lead-in phase. Previous in vitro studies have demonstrated that CAB is primarily metabolized via glucuronidation by uridine diphosphate glucuronosyltransferase (UGT) 1A1 and 1A9. In this study, we performed next-generation sequencing of genomic DNA isolated from the HPTN 077 participants to explore the variants within UGT1A1 and UGT1A9. Additionally, to enable correlation of UGT1A1 and UGT1A9 genotypes with plasma CAB-glucuronide levels, we quantified glucuronidated CAB following both oral administration of CAB and intramuscular injection of long-acting CAB. From these studies, 48 previously unreported variants of UGT1A1 and UGT1A9 were detected. Notably, 5/68 individuals carried a UGT1A1 454C>A variant that resulted in amino acid substitution P152T, and the use of in silico tools predicted a deleterious effect of the P152T substitution. Thus, the impact of this mutant on a range of UGT1A1 substrates was tested using a COS-7 cell-based assay. The glucuronide conjugates of CAB, dolutegravir, and raltegravir, were not formed in the COS-7 cells expressing the UGT1A1 P152T mutant. Further, formation of glucuronides of raloxifene and 7-ethyl-10-hydroxycamptothecin were reduced in the cells expressing the UGT1A1 P152T mutant. Using the same approach, we tested the activities of two UGT1A9 mutants, UGT1A9 H217Y and UGT1A9 R464G, and found that these mutations were tolerated and decreased function, respectively. These data provide insight into previously unreported genetic variants of UGT1A1 and UGT1A9.
- Published
- 2021
7. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077.
- Author
-
Tolley, Elizabeth, Zangeneh, Sahar, Chau, Gordon, Eron, Joe, Grinsztejn, Beatriz, Humphries, Hilton, Liu, Albert, Siegel, Marc, Bertha, Maseko, Panchia, Ravindre, Li, Sue, Cottle, Leslie, Rinehart, Alex, Margolis, David, Jennings, Andrea, McCauley, Marybeth, and Landovitz, Raphael
- Subjects
Acceptability ,Clinical trial ,Females ,HIV prevention ,Injectable ,Males ,PrEP ,Adult ,Anti-HIV Agents ,Double-Blind Method ,Female ,HIV Infections ,Humans ,Injections ,Male ,Middle Aged ,Patient Acceptance of Health Care ,Patient Participation ,Pre-Exposure Prophylaxis ,Pyridones ,Treatment Outcome - Abstract
Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.
- Published
- 2020
8. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus–uninfected Individuals in HPTN 077
- Author
-
Landovitz, Raphael J, Zangeneh, Sahar Z, Chau, Gordon, Grinsztejn, Beatriz, Eron, Joseph J, Dawood, Halima, Magnus, Manya, Liu, Albert Y, Panchia, Ravindre, Hosseinipour, Mina C, Kofron, Ryan, Margolis, David A, Rinehart, Alex, Adeyeye, Adeola, Burns, David, McCauley, Marybeth, Cohen, Myron S, and Currier, Judith S
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,HIV/AIDS ,Clinical Trials and Supportive Activities ,Clinical Research ,Nutrition ,Prevention ,Obesity ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Metabolic and endocrine ,Infection ,Good Health and Well Being ,Anti-HIV Agents ,HIV ,HIV Infections ,Humans ,Pyridones ,Weight Gain ,cabotegravir ,CAB ,weight gain ,HIV uninfected ,Biological Sciences ,Medical and Health Sciences ,Microbiology ,Clinical sciences - Abstract
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
- Published
- 2020
9. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
- Author
-
Riou, Catherine, primary, Bhiman, Jinal N., additional, Ganga, Yashica, additional, Sawry, Shobna, additional, Ayres, Frances, additional, Baguma, Richard, additional, Balla, Sashkia R., additional, Benede, Ntombi, additional, Bernstein, Mallory, additional, Besethi, Asiphe S., additional, Cele, Sandile, additional, Crowther, Carol, additional, Dhar, Mrinmayee, additional, Geyer, Sohair, additional, Gill, Katherine, additional, Grifoni, Alba, additional, Hermanus, Tandile, additional, Kaldine, Haajira, additional, Keeton, Roanne S., additional, Kgagudi, Prudence, additional, Khan, Khadija, additional, Lazarus, Erica, additional, Le Roux, Jean, additional, Lustig, Gila, additional, Madzivhandila, Mashudu, additional, Magugu, Siyabulela F. J., additional, Makhado, Zanele, additional, Manamela, Nelia P., additional, Mkhize, Qiniso, additional, Mosala, Paballo, additional, Motlou, Thopisang P., additional, Mutavhatsindi, Hygon, additional, Mzindle, Nonkululeko B., additional, Nana, Anusha, additional, Nesamari, Rofhiwa, additional, Ngomti, Amkele, additional, Nkayi, Anathi A., additional, Nkosi, Thandeka P., additional, Omondi, Millicent A., additional, Panchia, Ravindre, additional, Patel, Faeezah, additional, Sette, Alessandro, additional, Singh, Upasna, additional, van Graan, Strauss, additional, Venter, Elizabeth M., additional, Walters, Avril, additional, Moyo-Gwete, Thandeka, additional, Richardson, Simone I., additional, Garrett, Nigel, additional, Rees, Helen, additional, Bekker, Linda-Gail, additional, Gray, Glenda, additional, Burgers, Wendy A., additional, Sigal, Alex, additional, Moore, Penny L., additional, and Fairlie, Lee, additional
- Published
- 2024
- Full Text
- View/download PDF
10. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
- Author
-
Landovitz, Raphael J, Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Hendrix, Craig W, Eshleman, Susan H, Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Spreen, William R, Cohen, Myron S, McCauley, Marybeth, and Eron, Joseph J
- Subjects
Humans ,HIV Infections ,Pyridones ,Delayed-Action Preparations ,Anti-HIV Agents ,Drug Monitoring ,Treatment Outcome ,Injections ,Intramuscular ,Drug Administration Schedule ,Risk Assessment ,Risk Factors ,Double-Blind Method ,Adolescent ,Adult ,Aged ,Middle Aged ,Malawi ,South Africa ,United States ,Brazil ,Female ,Male ,Young Adult ,Injections ,Intramuscular ,General & Internal Medicine ,Medical and Health Sciences - Abstract
BackgroundCabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular (IM) administration, which delivers prolonged plasma exposure to the drug after IM injection. HIV Prevention Trials Network study 077 (HPTN 077) evaluated the safety, tolerability, and pharmacokinetics of CAB LA in HIV-uninfected males and females at 8 sites in Brazil, Malawi, South Africa, and the United States.Methods and findingsHPTN 077 was a double-blind, placebo-controlled phase 2a trial. Healthy individuals age 18-65 years at low HIV risk were randomized (3:1) to receive CAB or placebo (PBO). In the initial oral phase, participants received 1 daily oral tablet (CAB or PBO) for 4 weeks. Those without safety concerns in the oral phase continued and received injections in the injection phase (Cohort 1: 3 injections of CAB LA 800 mg or 0.9% saline as PBO IM every 12 weeks for 3 injection cycles; Cohort 2: CAB LA 600 mg or PBO IM for 5 injection cycles; the first 2 injections in Cohort 2 were separated by 4 weeks, the rest by 8 weeks). The primary analysis included weeks 5 to 41 of study participation, encompassing the injection phase. The cohorts were enrolled sequentially. Primary outcomes were safety and tolerability. Secondary outcomes included pharmacokinetics and events occurring during the oral and injection phases. Between February 9, 2015, and May 27, 2016, the study screened 443 individuals and enrolled 110 participants in Cohort 1 and 89 eligible participants in Cohort 2. Participant population characteristics were as follows: 66% female at birth; median age 31 years; 27% non-Hispanic white, 41% non-Hispanic black, 24% Hispanic/Latino, 3% Asian, and 6% mixed/other; and 6 transgender men and 1 transgender woman. Twenty-two (11%) participants discontinued the oral study product; 6 of these were for clinical or laboratory adverse events (AEs). Of those who received at least 1 CAB LA injection, 80% of Cohort 1 and 92% of Cohort 2 participants completed all injections; injection course completion rates were not different from those in the PBO arm. Injection site reactions (ISRs) were common (92% of Cohort 1 and 88% of Cohort 2 participants who received CAB LA reported any ISR). ISRs were mostly Grade 1 (mild) to Grade 2 (moderate), and 1 ISR event (Cohort 1) led to product discontinuation. Grade 2 or higher ISRs were the only AEs reported more commonly among CAB LA recipients than PBO recipients. Two Grade 3 (severe) ISRs occurred in CAB recipients, 1 in each cohort, but did not lead to product discontinuation in either case. Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. Participants in Cohort 2 (unlike Cohort 1) consistently met prespecified pharmacokinetic targets of at least 95% of participants maintaining CAB trough concentrations above PA-IC90, and 80% maintaining trough concentrations above 4× PA-IC90. Study limitations include a modest sample size, a short course of injections, and a low-risk study population.ConclusionsIn this study, CAB LA was well tolerated at the doses and dosing intervals used. ISRs were common, but infrequently led to product discontinuation. CAB LA 600 mg every 8 weeks met pharmacokinetic targets for both male and female study participants. The safety and pharmacokinetic results observed support the further development of CAB LA, and efficacy studies of CAB LA for HIV treatment and prevention are in progress.Trial registrationClinicalTrials.gov Registry: ClinicalTrials.gov Trial number: NCT02178800.
- Published
- 2018
11. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
- Author
-
Asmelash, Aida, Sehurutshi, Alice, Baguma, Allan, Marais, Anita, Kawoozo, Barbarah, Malinga, Bongiwe Prudence, Mirembe, Brenda Gati, Okech, Brenda, Esterhuizen, Bryan, Murombedzi, Caroline, Gadama, Daphne, Hwengwere, Eldinah, Roos, Elizabeth, Magada, Elizabeth S, Shava, Emily, Piwowar-Manning, Estelle, Tahuringana, Eunice, Muhlanga, Felix GS, Conradie, Francesca, Angira, Frank, Nanyonjo, Gertrude, Kistnasami, Girisha, Mvula, Hazzie, Naidoo, Ishana, Horak, Jaco, Jere, Jane, Moodley, Jeeva, Shin, Katie, Nel, Kerry, Bokoch, Kevin, Birungi, Lilian, Emel, Lynda, Monametsi, Maletsatsi, Sibanda, Marvelous, Mutambanengwe, Mercy, Chitukuta, Miria, Matimbira, Moleen, Bhondai-Mhuri, Muchaneta, Sibisi, Ncamsile, Morar, Neetha, Mudzonga, Netsai, Natureeba, Paul, Richardson, Paul, Musara, Petina, Macdonald, Pippa, Nkambule, Rejoice, Mosime, Repelang, White, Rhonda, Berhanu, Ribka, Ncube-Sihlongonyane, Ritha, Sekabira, Rogers, Siva, Samantha, Pillay, Saresha, Govender, Shamelle, Bamweyana, Sheiala, Nzimande, Siyabonga, Innes, Steve, Dadabhai, Sufia, Samandari, Taraz, Tembo, Tchangani, Lungu Mabedi, Thandie, Chirenda, Thandiwe, Chidemo, Tinashe, Mudhune, Victor, Naidoo, Vikesh, Samaneka, Wadzanai, Agyei, Yaw, Musodza, Yeukai, Fourie, Yolandie, Gaffoor, Zakir, Delany-Moretlwe, Sinead, Hughes, James P, Bock, Peter, Ouma, Samuel Gurrion, Hunidzarira, Portia, Kalonji, Dishiki, Kayange, Noel, Makhema, Joseph, Mandima, Patricia, Mathew, Carrie, Spooner, Elizabeth, Mpendo, Juliet, Mukwekwerere, Pamela, Mgodi, Nyaradzo, Ntege, Patricia Nahirya, Nair, Gonasagrie, Nakabiito, Clemensia, Nuwagaba-Biribonwoha, Harriet, Panchia, Ravindre, Singh, Nishanta, Siziba, Bekezela, Farrior, Jennifer, Rose, Scott, Anderson, Peter L, Eshleman, Susan H, Marzinke, Mark A, Hendrix, Craig W, Beigel-Orme, Stephanie, Hosek, Sybil, Tolley, Elizabeth, Sista, Nirupama, Adeyeye, Adeola, Rooney, James F, Rinehart, Alex, Spreen, William R, Smith, Kimberly, Hanscom, Brett, Cohen, Myron S, and Hosseinipour, Mina C
- Published
- 2022
- Full Text
- View/download PDF
12. The fourth generation AlereTM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples
- Author
-
Livant, Edward, Heaps, Amy, Kelly, Cliff, Maharaj, Rashika, Samsunder, Natasha, Nhlangulela, Lindiwe, Karugaba, Patrick, Panchia, Ravindre, Marrazzo, Jeanne, Chirenje, Zvavahera Mike, Parikh, Urvi M, and Team, on behalf of the VOICE Study
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Infectious Diseases ,Prevention ,Clinical Research ,HIV/AIDS ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Infection ,HIV Antibodies ,HIV Infections ,HIV-1 ,Humans ,Immunoassay ,Pre-Exposure Prophylaxis ,Reproducibility of Results ,Sensitivity and Specificity ,Serologic Tests ,Virology ,Acute infection ,4th generation rapid test ,Pre-exposure prophylaxis ,HIV confirmatory test ,HIV diagnostics ,VOICE Study Team ,Microbiology ,Clinical Sciences ,Clinical sciences ,Medical microbiology - Abstract
BackgroundEarly and accurate detection of HIV is crucial when using pre-exposure prophylaxis (PrEP) for HIV prevention to avoid PrEP initiation in acutely infected individuals and to minimize the risk of drug resistance in individuals with breakthrough infection.ObjectiveTo determine if fourth-generation antigen/antibody (Ag/Ab) rapid diagnostic tests (RDT) would have detected HIV infection earlier than the third-generation RDT used in MTN-003 (VOICE).Study design5029 VOICE participants were evaluated with third-generation Alere Determine™ HIV-1/2, OraQuick ADVANCE® Rapid HIV-1/2, Uni-Gold™ Recombigen® HIV-1/2 and Bio-Rad GS HIV-1/2+O EIA; and fourth-generation Alere Determine™ HIV-1/2 Ag/Ab Combo, Conformité Européene (CE)-Marked Alere™ HIV Combo and Bio-Rad HIV Combo Ag/Ab EIA. Multispot®, GS HIV-1 Western Blot (WB) and Geenius™ (Bio-Rad) were also evaluated.ResultsOf 57 antibody-negative pre-seroconversion plasma samples with HIV RNA >20 copies/mL identified, 16 (28%) were reactive by CE-Marked Alere™ HIV Combo (1 Ab; 9 Ag; 6 Ag/Ab reactive) and 4 (7%) by Alere Determine™ HIV-1/2 Ag/Ab Combo (2 Ab; 2 Ag; 0 Ag/Ab reactive) (p=0.0005). Multispot® confirmed only 1 of 16 acute infections while WB and Geenius™ confirmed none. GS HIV Combo Ag/Ab EIA identified 27 of 57 (47%) pre-seroconversion RNA-positive samples.ConclusionIn VOICE, 28% of infections missed by current third-generation RDT would have been identified with the use of CE-Marked Alere™ HIV Combo. Geenius™, Multispot® and WB were all insensitive (
- Published
- 2017
13. Uptake of antiretroviral treatment and viral suppression among men who have sex with men and transgender women in sub-Saharan Africa in an observational cohort study: HPTN 075
- Author
-
Palumbo, Philip J., Zhang, Yinfeng, Clarke, William, Breaud, Autumn, Sivay, Mariya, Cummings, Vanessa, Hamilton, Erica L., Guo, Xu, Ogendo, Arthur, Kayange, Noel, Panchia, Ravindre, Dominguez, Karen, Chen, Ying Q., Sandfort, Theodorus G.M., and Eshleman, Susan H.
- Published
- 2021
- Full Text
- View/download PDF
14. Antiretroviral Therapy for the Prevention of HIV-1 Transmission
- Author
-
Cohen, Myron S, Chen, Ying Q, McCauley, Marybeth, Gamble, Theresa, Hosseinipour, Mina C, Kumarasamy, Nagalingeswaran, Hakim, James G, Kumwenda, Johnstone, Grinsztejn, Beatriz, Pilotto, Jose HS, Godbole, Sheela V, Chariyalertsak, Suwat, Santos, Breno R, Mayer, Kenneth H, Hoffman, Irving F, Eshleman, Susan H, Piwowar-Manning, Estelle, Cottle, Leslie, Zhang, Xinyi C, Makhema, Joseph, Mills, Lisa A, Panchia, Ravindre, Faesen, Sharlaa, Eron, Joseph, Gallant, Joel, Havlir, Diane, Swindells, Susan, Elharrar, Vanessa, Burns, David, Taha, Taha E, Nielsen-Saines, Karin, Celentano, David D, Essex, Max, Hudelson, Sarah E, Redd, Andrew D, and Fleming, Thomas R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Immunology ,Medical Microbiology ,Prevention ,Clinical Research ,Infectious Diseases ,Clinical Trials and Supportive Activities ,HIV/AIDS ,Infection ,Good Health and Well Being ,Adult ,Anti-Retroviral Agents ,Disease Transmission ,Infectious ,Female ,Follow-Up Studies ,HIV Infections ,HIV Seropositivity ,HIV-1 ,Humans ,Intention to Treat Analysis ,Kaplan-Meier Estimate ,Male ,Middle Aged ,Risk ,Sexual Partners ,Young Adult ,HPTN 052 Study Team ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundAn interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. ART was then offered to all patients with HIV-1 infection (index participants). The study included more than 5 years of follow-up to assess the durability of such therapy for the prevention of HIV-1 transmission.MethodsWe randomly assigned 1763 index participants to receive either early or delayed ART. In the early-ART group, 886 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic millimeter). In the delayed-ART group, 877 participants started therapy after two consecutive CD4+ counts fell below 250 cells per cubic millimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defining illness) developed. The primary study end point was the diagnosis of genetically linked HIV-1 infection in the previously HIV-1-negative partner in an intention-to-treat analysis.ResultsIndex participants were followed for 10,031 person-years; partners were followed for 8509 person-years. Among partners, 78 HIV-1 infections were observed during the trial (annual incidence, 0.9%; 95% confidence interval [CI], 0.7 to 1.1). Viral-linkage status was determined for 72 (92%) of the partner infections. Of these infections, 46 were linked (3 in the early-ART group and 43 in the delayed-ART group; incidence, 0.5%; 95% CI, 0.4 to 0.7) and 26 were unlinked (14 in the early-ART group and 12 in the delayed-ART group; incidence, 0.3%; 95% CI, 0.2 to 0.4). Early ART was associated with a 93% lower risk of linked partner infection than was delayed ART (hazard ratio, 0.07; 95% CI, 0.02 to 0.22). No linked infections were observed when HIV-1 infection was stably suppressed by ART in the index participant.ConclusionsThe early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners. (Funded by the National Institute of Allergy and Infectious Diseases; HPTN 052 ClinicalTrials.gov number, NCT00074581 .).
- Published
- 2016
15. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
- Author
-
Landovitz, Raphael J, Li, Sue, Eron, Joseph J, Jr, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Eshleman, Susan H, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Cohen, Myron S, McCauley, Marybeth, and Hendrix, Craig W
- Published
- 2020
- Full Text
- View/download PDF
16. The feasibility of recruiting and retaining men who have sex with men and transgender women in a multinational prospective HIV prevention research cohort study in sub-Saharan Africa (HPTN 075)
- Author
-
Sandfort, Theodorus G.M., Hamilton, Erica L., Marais, Anita, Guo, Xu, Sugarman, Jeremy, Chen, Ying Q., Cummings, Vanessa, Dadabhai, Sufia, Dominguez, Karen, Panchia, Ravindre, Schnabel, David, Zulu, Fatima, Reynolds, Doerieyah, Radebe, Oscar, Mbeda, Calvin, Kamba, Dunker, Kanyemba, Brian, Ogendo, Arthur, Stirratt, Michael, Chege, Wairimu, Lucas, Jonathan, Fawzy, Maria, Mckinstry, Laura A., and Eshleman, Susan H.
- Subjects
Transgender people -- Health aspects ,HIV infections -- Prevention ,MSM (Men who have sex with men) -- Health aspects ,Medical research volunteers -- Management ,Company business management ,Health - Abstract
Introduction: Men who have sex with men (MSM) and transgender women (TGW) in sub-Saharan Africa (SSA) are profoundly affected by HIV with high HIV prevalence and incidence. This population also faces strong social stigma and legal barriers, potentially impeding participation in research. To date, few multi-country longitudinal HIV research studies with MSM/TGW have been conducted in SSA. Primary objective of the HIV Prevention Trials Network (HPTN) 075 study was to assess feasibility of recruiting and retaining a multinational prospective cohort of MSM/TGW in SSA for HIV prevention research. Methods: HPTN 075, conducted from 2015 to 2017, was designed to enroll 400 MSM/TGW at four sites in SSA (100 per site: Kisumu, Kenya; Blantyre, Malawi; Cape Town, South Africa; and Soweto, South Africa). The number of HIV-positive persons was capped at 20 per site; HIV-positive persons already in care were excluded from participation. The one-year study included five biobehavioural assessments. Community-based input and risk mitigation protocols were included in study design and conduct. Results: Of 624 persons screened, 401 were enrolled. One in five participants was classified as transgender. Main reasons for ineligibility included: (a) being HIV positive after the cap was reached (29.6%); (b) not reporting anal intercourse with a man in the preceding three months (20.6%); and (c) being HIV positive and already in care (17.5%). Five (1.2%) participants died during the study (unrelated to study participation). 92.9% of the eligible participants (368/396) completed the final study visit and 86.1% participated in all visits. The main, overlapping reasons for early termination included being (a) unable to adhere to the visit schedule, predominantly because of relocation (46.4%), and (b) unable to contact the participant (32.1%). Participants reported strong motivation to participate and few participation barriers. Four participants reported social harms (loss of confidentiality and sexual harassment by study staff) that were successfully addressed. Conclusions: HPTN 075 successfully enrolled a multinational sample of MSM/TGW in SSA in a prospective HIV prevention research study with a high retention rate and few documented social harms. This supports the feasibility of conducting large-scale research trials in this population to address its urgent, unmet HIV prevention needs. Keywords: HIV; closed cohort study; men who have sex with men; transgender women; sub-Saharan Africa, 1 | INTRODUCTION In sub-Saharan Africa (SSA), there is increasing recognition of the HIV burden among men who have sex with men (MSM) and transgender women (TGW) and their role [...]
- Published
- 2020
- Full Text
- View/download PDF
17. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
- Author
-
Riou, Catherine, primary, Bhiman, Jinal N, additional, Ganga, Yashica, additional, Sawry, Shobna, additional, Ayres, Frances, additional, Baguma, Richard, additional, Balla, Sashkia R, additional, Benede, Ntombi, additional, Bernstein, Mallory, additional, Besethi, Asiphe S, additional, Cele, Sandile, additional, Crowther, Carol, additional, Dhar, Mrinmayee, additional, Geyer, Sohair, additional, Gill, Katherine, additional, Grifoni, Alba, additional, Hermanus, Tandile, additional, Kaldine, Haajira, additional, Keeton, Roanne S, additional, Kgagudi, Prudence, additional, Khan, Khadija, additional, Lazarus, Erica, additional, Le Roux, Jean, additional, Lustig, Gila, additional, Madzivhandila, Mashudu, additional, Magugu, Siyabulela FJ, additional, Makhado, Zanele, additional, Manamela, Nelia P, additional, Mkhize, Qiniso, additional, Mosala, Paballo, additional, Motlou, Thopisang P, additional, Mutavhatsindi, Hygon, additional, Mzindle, Nonkululeko B, additional, Nana, Anusha, additional, Nesamari, Rofhiwa, additional, Ngomti, Amkele, additional, Nkayi, Anathi A, additional, Nkosi, Thandeka P, additional, Omondi, Millicent A, additional, Panchia, Ravindre, additional, Patel, Faeezah, additional, Sette, Alessandro, additional, Singh, Upasna, additional, van Graan, Strauss, additional, Venter, Elizabeth M., additional, Walters, Avril, additional, Moyo-Gwete, Thandeka, additional, Richardson, Simone I., additional, Garrett, Nigel, additional, Rees, Helen, additional, Bekker, Linda-Gail, additional, Gray, Glenda, additional, Burgers, Wendy A., additional, Sigal, Alex, additional, Moore, Penny L, additional, and Fairlie, Lee, additional
- Published
- 2023
- Full Text
- View/download PDF
18. HIV Incidence Among Pregnant and Nonpregnant Women in the FACTS-001 Trial: Implications for HIV Prevention, Especially PrEP Use
- Author
-
Rees, Helen, Chersich, Matthew Francis, Munthali, Richard J., Brumskine, William, Palanee-Phillips, Thesla, Nkala, Busi, Ahmed, Khatija, Sebe, Modulakgotla, Mabude, Zonke, Nchabeleng, Maphoshane, Bekker, Linda-Gail, Kotze, Philip, Mogodiri, Thembisile, Naidoo, Ishana, Panchia, Ravindre, Myer, Landon, Lombard, Carl, Doncel, Gustavo F., Gray, Glenda, and Delany-Moretlwe, Sinead
- Published
- 2021
- Full Text
- View/download PDF
19. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial
- Author
-
Delany-Moretlwe, Sinead, Lombard, Carl, Baron, Deborah, Bekker, Linda-Gail, Nkala, Busi, Ahmed, Khatija, Sebe, Modulakgotla, Brumskine, William, Nchabeleng, Maposhane, Palanee-Philips, Thesla, Ntshangase, Julius, Sibiya, Sidney, Smith, Emilee, Panchia, Ravindre, Myer, Landon, Schwartz, Jill L, Marzinke, Mark, Morris, Lynn, Brown, Elizabeth R, Doncel, Gustavo F, Gray, Glenda, and Rees, Helen
- Published
- 2018
- Full Text
- View/download PDF
20. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
- Author
-
Grinsztejn, Beatriz, Hosseinipour, Mina C, Ribaudo, Heather J, Swindells, Susan, Eron, Joseph, Chen, Ying Q, Wang, Lei, Ou, San-San, Anderson, Maija, McCauley, Marybeth, Gamble, Theresa, Kumarasamy, Nagalingeshwaran, Hakim, James G, Kumwenda, Johnstone, Pilotto, Jose HS, Godbole, Sheela V, Chariyalertsak, Suwat, de Melo, Marineide Gonçalves, Mayer, Kenneth H, Eshleman, Susan H, Piwowar-Manning, Estelle, Makhema, Joseph, Mills, Lisa A, Panchia, Ravindre, Sanne, Ian, Gallant, Joel, Hoffman, Irving, Taha, Taha E, Nielsen-Saines, Karin, Celentano, David, Essex, Max, Havlir, Diane, Cohen, Myron S, and Team, the HPTN 052-ACTG Study
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Immunology ,Medical Microbiology ,Infectious Diseases ,Clinical Research ,Clinical Trials and Supportive Activities ,HIV/AIDS ,Prevention ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,AIDS-Related Opportunistic Infections ,Acquired Immunodeficiency Syndrome ,Adult ,Anti-Retroviral Agents ,CD4 Lymphocyte Count ,Cardiovascular Diseases ,Diabetes Mellitus ,Type 2 ,Disease Progression ,Drug Administration Schedule ,Female ,HIV-1 ,Humans ,Intention to Treat Analysis ,Kaplan-Meier Estimate ,Kidney Failure ,Chronic ,Liver Diseases ,Male ,Neoplasms ,Proportional Hazards Models ,Time Factors ,Tuberculosis ,Pulmonary ,Young Adult ,HPTN 052-ACTG Study Team ,Public Health and Health Services ,Microbiology ,Clinical sciences ,Medical microbiology ,Epidemiology - Abstract
BackgroundUse of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of HIV-1. However, the best time to initiate antiretroviral treatment to reduce progression of HIV-1 infection or non-AIDS clinical events is unknown. We reported previously that early antiretroviral treatment reduced HIV-1 transmission by 96%. We aimed to compare the effects of early and delayed initiation of antiretroviral treatment on clinical outcomes.MethodsThe HPTN 052 trial is a randomised controlled trial done at 13 sites in nine countries. We enrolled HIV-1-serodiscordant couples to the study and randomly allocated them to either early or delayed antiretroviral treatment by use of permuted block randomisation, stratified by site. Random assignment was unblinded. The HIV-1-infected member of every couple initiated antiretroviral treatment either on entry into the study (early treatment group) or after a decline in CD4 count or with onset of an AIDS-related illness (delayed treatment group). Primary events were AIDS clinical events (WHO stage 4 HIV-1 disease, tuberculosis, and severe bacterial infections) and the following serious medical conditions unrelated to AIDS: serious cardiovascular or vascular disease, serious liver disease, end-stage renal disease, new-onset diabetes mellitus, and non-AIDS malignant disease. Analysis was by intention-to-treat. This trial is registered with ClinicalTrials.gov, number NCT00074581.Findings1763 people with HIV-1 infection and a serodiscordant partner were enrolled in the study; 886 were assigned early antiretroviral treatment and 877 to the delayed treatment group (two individuals were excluded from this group after randomisation). Median CD4 counts at randomisation were 442 (IQR 373-522) cells per μL in patients assigned to the early treatment group and 428 (357-522) cells per μL in those allocated delayed antiretroviral treatment. In the delayed group, antiretroviral treatment was initiated at a median CD4 count of 230 (IQR 197-249) cells per μL. Primary clinical events were reported in 57 individuals assigned to early treatment initiation versus 77 people allocated to delayed antiretroviral treatment (hazard ratio 0·73, 95% CI 0·52-1·03; p=0·074). New-onset AIDS events were recorded in 40 participants assigned to early antiretroviral treatment versus 61 allocated delayed initiation (0·64, 0·43-0·96; p=0·031), tuberculosis developed in 17 versus 34 patients, respectively (0·49, 0·28-0·89, p=0·018), and primary non-AIDS events were rare (12 in the early group vs nine with delayed treatment). In total, 498 primary and secondary outcomes occurred in the early treatment group (incidence 24·9 per 100 person-years, 95% CI 22·5-27·5) versus 585 in the delayed treatment group (29·2 per 100 person-years, 26·5-32·1; p=0·025). 26 people died, 11 who were allocated to early antiretroviral treatment and 15 who were assigned to the delayed treatment group.InterpretationEarly initiation of antiretroviral treatment delayed the time to AIDS events and decreased the incidence of primary and secondary outcomes. The clinical benefits recorded, combined with the striking reduction in HIV-1 transmission risk previously reported, provides strong support for earlier initiation of antiretroviral treatment.FundingUS National Institute of Allergy and Infectious Diseases.
- Published
- 2014
21. Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075
- Author
-
Fogel, Jessica M., Sandfort, Theodorus, Zhang, Yinfeng, Guo, Xu, Clarke, William, Breaud, Autumn, Cummings, Vanessa, Hamilton, Erica L., Ogendo, Arthur, Kayange, Noel, Panchia, Ravindre, Dominguez, Karen, Chen, Ying Q., and Eshleman, Susan H.
- Published
- 2019
- Full Text
- View/download PDF
22. HIV risk perception and sexual behavior among HIV-uninfected men and transgender women who have sex with men in sub-Saharan Africa: Findings from the HPTN 075 qualitative sub-study
- Author
-
Mbilizi Chimwaza, Yamikani R., primary, Dadabhai, Sufia S., additional, Nyondo Mipando, Alinane L., additional, Mbeda, Calvin, additional, Panchia, Ravindre, additional, Lucas, Jonathan P., additional, Chege, Wairimu, additional, Hamilton, Erica L., additional, and Sandfort, Theodorus G. M., additional
- Published
- 2022
- Full Text
- View/download PDF
23. Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa
- Author
-
Zhang, Yinfeng, Fogel, Jessica M., Guo, Xu, Clarke, William, Breaud, Autumn, Cummings, Vanessa, Hamilton, Erica L., Ogendo, Arthur, Kayange, Noel, Panchia, Ravindre, Dominguez, Karen, Chen, Ying Q., Sandfort, Theodorus, and Eshleman, Susan H.
- Published
- 2018
- Full Text
- View/download PDF
24. Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052
- Author
-
Greer, Amy E., Ou, San-San, Wilson, Ethan, Piwowar-Manning, Estelle, Forman, Michael S., McCauley, Marybeth, Gamble, Theresa, Ruangyuttikarn, Cholticha, Hosseinipour, Mina C., Kumarasamy, Nagalingeswaran, Nyirenda, Mulinda, Grinsztejn, Beatriz, Pilotto, Jose Henrique, Kosashunhanan, Natthapol, Gonçalves de Melo, Marineide, Makhema, Joseph, Akelo, Victor, Panchia, Ravindre, Badal-Faesen, Sharlaa, Chen, Ying Q., Cohen, Myron S., Eshleman, Susan H., Thio, Chloe L., and Valsamakis, Alexandra
- Published
- 2017
- Full Text
- View/download PDF
25. Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network 052)
- Author
-
Fogel, Jessica M., Wang, Lei, Parsons, Teresa L., Ou, San-San, Piwowar-Manning, Estelle, Chen, Ying, Mudhune, Victor O., Hosseinipour, Mina C., Kumwenda, Johnstone, Hakim, James G., Chariyalertsak, Suwat, Panchia, Ravindre, Sanne, Ian, Kumarasamy, Nagalingeswaran, Grinsztejn, Beatriz, Makhema, Joseph, Pilotto, Jose, Santos, Breno R., Mayer, Kenneth H., McCauley, Marybeth, Gamble, Theresa, Bumpus, Namandjé N., Hendrix, Craig W., Cohen, Myron S., and Eshleman, Susan H.
- Published
- 2013
- Full Text
- View/download PDF
26. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
- Author
-
Delany-Moretlwe, Sinead, primary, Hughes, James P, additional, Bock, Peter, additional, Ouma, Samuel Gurrion, additional, Hunidzarira, Portia, additional, Kalonji, Dishiki, additional, Kayange, Noel, additional, Makhema, Joseph, additional, Mandima, Patricia, additional, Mathew, Carrie, additional, Spooner, Elizabeth, additional, Mpendo, Juliet, additional, Mukwekwerere, Pamela, additional, Mgodi, Nyaradzo, additional, Ntege, Patricia Nahirya, additional, Nair, Gonasagrie, additional, Nakabiito, Clemensia, additional, Nuwagaba-Biribonwoha, Harriet, additional, Panchia, Ravindre, additional, Singh, Nishanta, additional, Siziba, Bekezela, additional, Farrior, Jennifer, additional, Rose, Scott, additional, Anderson, Peter L, additional, Eshleman, Susan H, additional, Marzinke, Mark A, additional, Hendrix, Craig W, additional, Beigel-Orme, Stephanie, additional, Hosek, Sybil, additional, Tolley, Elizabeth, additional, Sista, Nirupama, additional, Adeyeye, Adeola, additional, Rooney, James F, additional, Rinehart, Alex, additional, Spreen, William R, additional, Smith, Kimberly, additional, Hanscom, Brett, additional, Cohen, Myron S, additional, Hosseinipour, Mina C, additional, Asmelash, Aida, additional, Sehurutshi, Alice, additional, Baguma, Allan, additional, Marais, Anita, additional, Kawoozo, Barbarah, additional, Malinga, Bongiwe Prudence, additional, Mirembe, Brenda Gati, additional, Okech, Brenda, additional, Esterhuizen, Bryan, additional, Murombedzi, Caroline, additional, Gadama, Daphne, additional, Hwengwere, Eldinah, additional, Roos, Elizabeth, additional, Magada, Elizabeth S, additional, Shava, Emily, additional, Piwowar-Manning, Estelle, additional, Tahuringana, Eunice, additional, Muhlanga, Felix GS, additional, Conradie, Francesca, additional, Angira, Frank, additional, Nanyonjo, Gertrude, additional, Kistnasami, Girisha, additional, Mvula, Hazzie, additional, Naidoo, Ishana, additional, Horak, Jaco, additional, Jere, Jane, additional, Moodley, Jeeva, additional, Shin, Katie, additional, Nel, Kerry, additional, Bokoch, Kevin, additional, Birungi, Lilian, additional, Emel, Lynda, additional, Monametsi, Maletsatsi, additional, Sibanda, Marvelous, additional, Mutambanengwe, Mercy, additional, Chitukuta, Miria, additional, Matimbira, Moleen, additional, Bhondai-Mhuri, Muchaneta, additional, Sibisi, Ncamsile, additional, Morar, Neetha, additional, Mudzonga, Netsai, additional, Natureeba, Paul, additional, Richardson, Paul, additional, Musara, Petina, additional, Macdonald, Pippa, additional, Nkambule, Rejoice, additional, Mosime, Repelang, additional, White, Rhonda, additional, Berhanu, Ribka, additional, Ncube-Sihlongonyane, Ritha, additional, Sekabira, Rogers, additional, Siva, Samantha, additional, Pillay, Saresha, additional, Govender, Shamelle, additional, Bamweyana, Sheiala, additional, Nzimande, Siyabonga, additional, Innes, Steve, additional, Dadabhai, Sufia, additional, Samandari, Taraz, additional, Tembo, Tchangani, additional, Lungu Mabedi, Thandie, additional, Chirenda, Thandiwe, additional, Chidemo, Tinashe, additional, Mudhune, Victor, additional, Naidoo, Vikesh, additional, Samaneka, Wadzanai, additional, Agyei, Yaw, additional, Musodza, Yeukai, additional, Fourie, Yolandie, additional, and Gaffoor, Zakir, additional
- Published
- 2022
- Full Text
- View/download PDF
27. Pulmonary TB: varying radiological presentations in individuals with HIV in Soweto, South Africa
- Author
-
Kistan, Jesne, Laher, Fatima, Otwombe, Kennedy, Panchia, Ravindre, Mawaka, Nohemie, Lebina, Limakatso, Diacon, Andreas, Kana, Bavesh, and Martinson, Neil
- Published
- 2017
- Full Text
- View/download PDF
28. Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial
- Author
-
Eshleman, Susan H., Hudelson, Sarah E., Redd, Andrew D., Swanstrom, Ronald, Ou, San-San, Zhang, Xinyi Cindy, Ping, Li-Hua, Piwowar-Manning, Estelle, Porcella, Stephen F., Sievers, Matthew F., Martens, Craig A., Bruno, Daniel, Dukhovlinova, Elena, McCauley, Marybeth, Gamble, Theresa, Fogel, Jessica M., Sabin, Devin, Quinn, Thomas C., Gunde, Laurence, Maliwichi, Madalitso, Nhando, Nehemiah, Akelo, Victor, Moyo, Sikhulile, Panchia, Ravindre, Kumarasamy, Nagalingeswaran, Chotirosniramit, Nuntisa, Melo, Marineide Gonçalves de, Pilotto, Jose, Grinsztejn, Beatriz, Mayer, Kenneth, Chen, Ying Q., Hughes, James P., and Cohen, Myron S.
- Published
- 2017
- Full Text
- View/download PDF
29. Cabotegravir for Prevention of HIV-1 in Women: Results From HPTN 084, a Phase III, Randomised Controlled Trial
- Author
-
Delany-Moretlwe, Sinead, primary, Hughes, James P., additional, Bock, Peter, additional, Ouma, Samuel Gurrion, additional, Hunidzarira, Portia, additional, Kalonji, Dishiki, additional, Kayange, Noel, additional, Makhema, Joseph, additional, Mandima, Patricia, additional, Mathew, Carrie, additional, Spooner, Elizabeth, additional, Mpendo, Juliet, additional, Mukwekwerere, Pamela, additional, Mgodi, Nyaradzo M., additional, Ntege, Patricia Nahirya, additional, Nair, Gonasagrie, additional, Nakabiito, Clemensia, additional, Nuwagaba-Biribonwoha, Harriet, additional, Panchia, Ravindre, additional, Singh, Nishanta, additional, Siziba, Bekezela, additional, Farrior, Jennifer, additional, Rose, Scott, additional, Berhanu, Rebecca, additional, Anderson, Peter L, additional, Agyei, Yaw, additional, Eshleman, Susan H., additional, Marzinke, Mark A., additional, Piwowar-Manning, Estelle, additional, Hendrix, Craig W., additional, Asmelash, Aida, additional, Conradie, Francesca, additional, Moorhouse, Michelle, additional, Richardson, Paul, additional, Beigel-Orme, Stephanie, additional, Emel, Lynda, additional, Bokoch, Kevin, additional, White, Rhonda, additional, Hosek, Sybil, additional, Tolley, Elizabeth, additional, Sista, Nirupama, additional, Shin, Katherine, additional, Adeyeye, Adeola, additional, Rooney, James, additional, Rinehart, Alex R., additional, Spreen, William R, additional, Smith, Kimberly, additional, Hanscom, Brett, additional, Cohen, Myron S., additional, and Hosseinipour, Mina C., additional
- Published
- 2022
- Full Text
- View/download PDF
30. Healthcare-related stigma among men who have sex with men and transgender women in sub-Saharan Africa participating in HIV Prevention Trials Network (HPTN) 075 study
- Author
-
Mbeda, Calvin, Ogendo, Arthur, Lando, Richard, Schnabel, David, Gust, Deborah A., Guo, Xu, Akelo, Victor, Dominguez, Karen, Panchia, Ravindre, Mbilizi, Yamikani, Chen, Ying, Chege, Wairimu, and Sandfort, Theo
- Subjects
Adult ,Male ,Malawi ,medicine.medical_specialty ,Health (social science) ,Sub saharan ,Social Psychology ,Attitude of Health Personnel ,Health Personnel ,Social Stigma ,Human immunodeficiency virus (HIV) ,Stigma (botany) ,HIV Infections ,medicine.disease_cause ,Transgender Persons ,Article ,Health Services Accessibility ,Transgender women ,Men who have sex with men ,Cohort Studies ,Sexual and Gender Minorities ,South Africa ,03 medical and health sciences ,Health services ,Discrimination, Psychological ,0302 clinical medicine ,Health care ,Retention in Care ,Humans ,Medicine ,030212 general & internal medicine ,Homosexuality, Male ,Aged ,030505 public health ,business.industry ,Public Health, Environmental and Occupational Health ,virus diseases ,Fear ,Middle Aged ,Patient Acceptance of Health Care ,Kenya ,Family medicine ,Female ,Prevention trials ,0305 other medical science ,business - Abstract
The inability to access health services when needed is a critical barrier to HIV prevention, treatment, and care among men who have sex with men (MSM) and transgender women (TGW). Using data collected in HPTN 075, we explored factors associated with any any experienced healthcare-related stigma. HPTN 075 was a cohort study to assess the feasibility of recruiting and retaining MSM and TGW in clinical trials in sub-Saharan Africa. Of 401 MSM and TGW enrolled at four sites (Kisumu, Kenya; Blantyre, Malawi; Cape Town, Soweto, South Africa) 397 contributed to the analysis (79.9% cis-gender and 20.1% TGW). Of these, (45.3%; 180/397) reported one or more of healthcare-related stigma experiences. Most frequently reported experiences included fear to seek healthcare services (36.3%) and avoiding seeking such services because of discovery of MSM status (29.2%). Few men and TGW (2.5%) reported having been denied health services because of having sex with men. In multivariable analysis, more participants in Soweto [adjusted odds ratio (AOR) = 2.60] and fewer participants in Blantyre (AOR = 0.27) reported any healthcare-related stigma experiences, in comparison to participants in Kisumu. MSM and TGW that did not have a supportive gay community to rely on were more likely to report any healthcare-related stigma experiences (AOR = 1.46), whereas MSM and TGW who reported high social support and who never had engaged in transactional sex were less likely to report such experiences (AOR = 0.76 and AOR = 0.43, respectively). Our results suggest that encouraging support groups for MSM and TGW as well as training and sensitizing healthcare staff, and the general community, on MSM and TGW health issues and cultural competence may reduce stigma, improve access to healthcare, which could ultimately reduce HIV transmission.
- Published
- 2020
31. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial
- Author
-
Sanne, Ian, Orrell, Catherine, Fox, Matthew P, Conradie, Francesca, Ive, Prudence, Zeinecker, Jennifer, Cornell, Morna, Heiberg, Christie, Ingram, Charlotte, Panchia, Ravindre, Rassool, Mohammed, Gonin, René, Stevens, Wendy, Truter, Handré, Dehlinger, Marjorie, van der Horst, Charles, McIntyre, James, and Wood, Robin
- Published
- 2010
- Full Text
- View/download PDF
32. Prevalence and Incidence of Sexually Transmitted Infection in Injectable Progestin Contraception Users in South Africa
- Author
-
Noguchi, Lisa M., primary, Marrazzo, Jeanne M., additional, Richardson, Barbara, additional, Hillier, Sharon L., additional, Balkus, Jennifer E., additional, Palanee-Phillips, Thesla, additional, Nair, Gonasagrie, additional, Panchia, Ravindre, additional, Piper, Jeanna, additional, Gomez, Kailazarid, additional, Ramjee, Gita, additional, and Chirenje, Z. Mike, additional
- Published
- 2021
- Full Text
- View/download PDF
33. Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052
- Author
-
Chagomerana, Maganizo B, primary, Hosseinipour, Mina C, additional, Pilotto, Jose Henrique, additional, Badal-Faesen, Sharlaa, additional, Nyirenda, Mulinda, additional, Shava, Emily, additional, Godbole, Sheela V, additional, Akelo, Victor, additional, Chariyalertsak, Suwat, additional, Panchia, Ravindre, additional, and Cohen, Myron, additional
- Published
- 2021
- Full Text
- View/download PDF
34. Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization
- Author
-
Liu, Gui, primary, Mugo, Nelly R., additional, Brown, Elizabeth R., additional, Mgodi, Nyaradzo M., additional, Chirenje, Zvavahera M., additional, Marrazzo, Jeanne M., additional, Winer, Rachel L., additional, Mansoor, Leila, additional, Palanee-Phillips, Thesla, additional, Siva, Samantha S., additional, Naidoo, Logashvari, additional, Jeenarain, Nitesha, additional, Gaffoor, Zakir, additional, Nair, Gonasagrie L., additional, Selepe, Pearl, additional, Nakabiito, Clemensia, additional, Mkhize, Baningi, additional, Mirembe, Brenda Gati, additional, Taljaard, Marthinette, additional, Panchia, Ravindre, additional, Baeten, Jared M., additional, Balkus, Jennifer E., additional, Hladik, Florian, additional, Celum, Connie L., additional, and Barnabas, Ruanne V., additional
- Published
- 2021
- Full Text
- View/download PDF
35. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
- Author
-
Tolley, Elizabeth E, Zangeneh, Sahar Z, Chau, Gordon, Eron, Joe, Grinsztejn, Beatriz, Humphries, Hilton, Liu, Albert, Siegel, Marc, Bertha, Maseko, Panchia, Ravindre, Li, Sue, Cottle, Leslie, Rinehart, Alex, Margolis, David, Jennings, Andrea, McCauley, Marybeth, and Landovitz, Raphael J
- Subjects
Adult ,Male ,Social Work ,Pyridones ,Anti-HIV Agents ,HIV prevention ,HIV Infections ,Injections ,Acceptability ,Double-Blind Method ,Females ,Clinical Research ,Behavioral and Social Science ,Humans ,Males ,Prevention ,Middle Aged ,Patient Acceptance of Health Care ,PrEP ,Clinical trial ,Treatment Outcome ,Injectable ,Good Health and Well Being ,Public Health and Health Services ,HIV/AIDS ,Female ,Pre-Exposure Prophylaxis ,Public Health ,Patient Participation - Abstract
Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.
- Published
- 2020
36. HIV incidence in a multinational cohort of men and transgender women who have sex with men in sub-Saharan Africa: Findings from HPTN 075
- Author
-
Sandfort, Theodorus G. M., primary, Mbilizi, Yamikani, additional, Sanders, Eduard J., additional, Guo, Xu, additional, Cummings, Vanessa, additional, Hamilton, Erica L., additional, Akelo, Victor, additional, Panchia, Ravindre, additional, Dominguez, Karen, additional, Stirratt, Michael J., additional, Chege, Wairimu, additional, Lucas, Jonathan, additional, Gaydos, Charlotte A., additional, Chen, Ying Q., additional, and Eshleman, Susan H., additional
- Published
- 2021
- Full Text
- View/download PDF
37. Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
- Author
-
Walensky, Rochelle P., Ross, Eric L., Kumarasamy, Nagalingeswaran, Wood, Robin, Noubary, Farzad, Paltiel, David A., Nakamura, Yoriko M., Godbole, Sheela V., Panchia, Ravindre, Sanne, Ian, Weinstein, Milton C., Losina, Elena, Mayer, Kenneth H., Chen, Ying Q., Wang, Lei, McCauley, Marybeth, Gamble, Theresa, Seage, George R., Cohen, Myron S., and Freedberg, Kenneth A.
- Published
- 2013
- Full Text
- View/download PDF
38. Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study
- Author
-
Sivay, Mariya V, primary, Palumbo, Philip J, additional, Zhang, Yinfeng, additional, Cummings, Vanessa, additional, Guo, Xu, additional, Hamilton, Erica L, additional, McKinstry, Laura, additional, Ogendo, Arthur, additional, Kayange, Noel, additional, Panchia, Ravindre, additional, Dominguez, Karen, additional, Chen, Ying Q, additional, Sandfort, Theodorus G M, additional, and Eshleman, Susan H, additional
- Published
- 2020
- Full Text
- View/download PDF
39. Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study.
- Author
-
Sivay, Mariya V, Palumbo, Philip J, Zhang, Yinfeng, Cummings, Vanessa, Guo, Xu, Hamilton, Erica L, McKinstry, Laura, Ogendo, Arthur, Kayange, Noel, Panchia, Ravindre, Dominguez, Karen, Chen, Ying Q, Sandfort, Theodorus G M, and Eshleman, Susan H
- Subjects
HIV infection transmission ,HIV infections ,PHYLOGENY ,SEQUENCE analysis ,GENETIC mutation ,VIRAL load ,DRUG resistance ,SUPERINFECTION ,DISEASE incidence ,GENE expression ,GENOTYPES ,DISEASE prevalence ,DESCRIPTIVE statistics ,MEN who have sex with men ,LOGISTIC regression analysis ,DATA analysis software ,LONGITUDINAL method - Abstract
Background The HIV Prevention Trials Network (HPTN) 075 study evaluated the feasibility of enrolling and retaining men who have sex with men (MSM) and transgender women (TGW) from Kenya, Malawi, and South Africa. During the study follow-up, 21 participants acquired human immunodeficiency virus (HIV) (seroconverters). We analyzed HIV subtype diversity, drug resistance, transmission dynamics, and HIV superinfection data among MSM and TGW enrolled in HPTN 075. Methods HIV genotyping and drug resistance testing were performed for participants living with HIV who had viral loads >400 copies/mL at screening (prevalent cases, n = 124) and seroconverters (n = 21). HIV pol clusters were identified using Cluster Picker. Superinfection was assessed by a longitudinal analysis of env and pol sequences generated by next-generation sequencing. Results HIV genotyping was successful for 123/124 prevalent cases and all 21 seroconverters. The major HIV subtypes were A1 (Kenya) and C (Malawi and South Africa). Major drug resistance mutations were detected in samples from 21 (14.6%) of 144 participants; the most frequent mutations were K103N and M184V/I. Phylogenetic analyses identified 11 clusters (2–6 individuals). Clusters included seroconverters only (n = 1), prevalent cases and seroconverters (n = 4), and prevalent cases only (n = 6). Superinfections were identified in 1 prevalent case and 2 seroconverters. The annual incidence of superinfection was higher among seroconverters than among prevalent cases, and was higher than the rate of primary HIV infection in the cohort. Conclusions This report provides important insights into HIV genetic diversity, drug resistance, and superinfection among MSM and TGW in sub-Saharan Africa. These findings may help to inform future HIV prevention interventions in these high-risk groups. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075
- Author
-
Sandfort, Theo G. M., primary, Dominguez, Karen, additional, Kayange, Noel, additional, Ogendo, Arthur, additional, Panchia, Ravindre, additional, Chen, Ying Q., additional, Chege, Wairimu, additional, Cummings, Vanessa, additional, Guo, Xu, additional, Hamilton, Erica L., additional, Stirratt, Michael, additional, and Eshleman, Susan H., additional
- Published
- 2019
- Full Text
- View/download PDF
41. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus–uninfected Individuals in HPTN 077
- Author
-
Landovitz, Raphael J, primary, Zangeneh, Sahar Z, additional, Chau, Gordon, additional, Grinsztejn, Beatriz, additional, Eron, Joseph J, additional, Dawood, Halima, additional, Magnus, Manya, additional, Liu, Albert Y, additional, Panchia, Ravindre, additional, Hosseinipour, Mina C, additional, Kofron, Ryan, additional, Margolis, David A, additional, Rinehart, Alex, additional, Adeyeye, Adeola, additional, Burns, David, additional, McCauley, Marybeth, additional, Cohen, Myron S, additional, and Currier, Judith S, additional
- Published
- 2019
- Full Text
- View/download PDF
42. Tail-Phase Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in HIV-Uninfected Adults: HPTN 077
- Author
-
Landovitz, Raphael, primary, Li, Sue, additional, Eron Jr., Joseph J., additional, Grinsztejn, Beatriz, additional, Dawood, Halima, additional, Liu, Albert Y., additional, Magnus, Manya, additional, Hosseinipour, Mina C., additional, Panchia, Ravindre, additional, Cottle, Leslie, additional, Chau, Gordon, additional, Richardson, Paul, additional, Marzinke, Mark A., additional, Eshleman, Susan, additional, Kofron, Ryan, additional, Adeyeye, Adeola, additional, Burns, David, additional, Rinehart, Alex R., additional, Margolis, David, additional, Cohen, Myron S., additional, McCauley, Marybeth, additional, and Hendrix, Craig W., additional
- Published
- 2019
- Full Text
- View/download PDF
43. Thymic Output and CD4 T-Cell Reconstitution in HIV-Infected Children on Early and Interrupted Antiretroviral Treatment: Evidence from the Children with HIV Early Antiretroviral Therapy Trial
- Author
-
Lewis, Joanna, Payne, Helen, Walker, A. Sarah, Otwombe, Kennedy, Gibb, Diana M., Babiker, Abdel G., Panchia, Ravindre, Cotton, Mark F., Violari, Avy, Klein, Nigel, and Callard, Robin E.
- Subjects
children ,thymus ,planned treatment interruption ,Immunology ,antiretroviral therapy ,CD4 T cells ,HIV ,CD4 count ,Original Research - Abstract
Objectives Early treatment of HIV-infected children and adults is important for optimal immune reconstitution. Infants’ immune systems are more plastic and dynamic than older children’s or adults’, and deserve particular attention. This study aimed to understand the response of the HIV-infected infant immune system to early antiretroviral therapy (ART) and planned ART interruption and re-start. Methods Data from HIV-infected children enrolled the CHER trial, starting ART aged between 6 and 12 weeks, was used to explore the effect of ART on immune reconstitution. We used linear and nonlinear regression and mixed-effects models to describe children’s CD4 trajectories and to identify predictors of CD4 count during early and interrupted ART. Results Early treatment arrested the decline in CD4 count but did not fully restore it to the levels observed in HIV-uninfected children. Treatment interruption at 40 or 96 weeks resulted in a rapid decline in CD4 T-cells, which on retreatment returned to levels observed before interruption. Naïve CD4 T-cell count was an important determinant of overall CD4 levels. A strong correlation was observed between thymic output and the stable CD4 count both before and after treatment interruption. Conclusions Early identification and treatment of HIV-infected infants is important to stabilize CD4 counts at the highest levels possible. Once stabilized, children’s CD4 counts appear resilient, with good potential for recovery following treatment interruption. The naïve T-cell pool and thymic production of naive cells are key determinants of children’s CD4 levels.
- Published
- 2017
44. Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075
- Author
-
Fogel, Jessica M., primary, Sandfort, Theodorus, additional, Zhang, Yinfeng, additional, Guo, Xu, additional, Clarke, William, additional, Breaud, Autumn, additional, Cummings, Vanessa, additional, Hamilton, Erica L., additional, Ogendo, Arthur, additional, Kayange, Noel, additional, Panchia, Ravindre, additional, Dominguez, Karen, additional, Chen, Ying Q., additional, and Eshleman, Susan H., additional
- Published
- 2018
- Full Text
- View/download PDF
45. HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052
- Author
-
Palumbo, Philip J., primary, Fogel, Jessica M., additional, Hudelson, Sarah E., additional, Wilson, Ethan A., additional, Hart, Stephen, additional, Hovind, Laura, additional, Piwowar-Manning, Estelle, additional, Wallis, Carole, additional, Papathanasopoulos, Maria A., additional, Morgado, Mariza G., additional, Saravanan, Shanmugam, additional, Tripathy, Srikanth, additional, Eron, Joseph J., additional, Gallant, Joel E., additional, McCauley, Marybeth, additional, Gamble, Theresa, additional, Hosseinipour, Mina C., additional, Kumarasamy, Nagalingeswaran, additional, Hakim, James G., additional, Pilotto, Jose H., additional, Kumwenda, Johnstone, additional, Akelo, Victor, additional, Godbole, Sheela V., additional, Santos, Breno R., additional, Grinsztejn, Beatriz, additional, Panchia, Ravindre, additional, Chariyalertsak, Suwat, additional, Makhema, Joseph, additional, Badal-Faesen, Sharlaa, additional, Chen, Ying Q., additional, Cohen, Myron S., additional, and Eshleman, Susan H., additional
- Published
- 2018
- Full Text
- View/download PDF
46. The fourth generation Alere TM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples
- Author
-
Livant, Edward, primary, Heaps, Amy, additional, Kelly, Cliff, additional, Maharaj, Rashika, additional, Samsunder, Natasha, additional, Nhlangulela, Lindiwe, additional, Karugaba, Patrick, additional, Panchia, Ravindre, additional, Marrazzo, Jeanne, additional, Chirenje, Zvavahera Mike, additional, and Parikh, Urvi M., additional
- Published
- 2017
- Full Text
- View/download PDF
47. HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial
- Author
-
Riddler, Sharon A., primary, Husnik, Marla, additional, Ramjee, Gita, additional, Premrajh, Anamika, additional, Tutshana, Bomkazi Onini, additional, Pather, Arendevi, additional, Siva, Samantha, additional, Jeenarain, Nitesha, additional, Nair, Gonasagrie, additional, Selepe, Pearl, additional, Kabwigu, Samuel, additional, Palanee-Phillips, Thesla, additional, Panchia, Ravindre, additional, Mhlanga, Felix, additional, Levy, Lisa, additional, Livant, Edward, additional, Patterson, Karen, additional, Elharrar, Vanessa, additional, and Balkus, Jennifer, additional
- Published
- 2017
- Full Text
- View/download PDF
48. Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052
- Author
-
Palumbo, Philip J., primary, Wilson, Ethan A., additional, Piwowar-Manning, Estelle, additional, McCauley, Marybeth, additional, Gamble, Theresa, additional, Kumwenda, Newton, additional, Makhema, Joseph, additional, Kumarasamy, Nagalingeswaran, additional, Chariyalertsak, Suwat, additional, Hakim, James G., additional, Hosseinipour, Mina C., additional, Melo, Marineide G., additional, Godbole, Sheela V., additional, Pilotto, Jose H., additional, Grinsztejn, Beatriz, additional, Panchia, Ravindre, additional, Chen, Ying Q., additional, Cohen, Myron S., additional, Eshleman, Susan H., additional, and Fogel, Jessica M., additional
- Published
- 2017
- Full Text
- View/download PDF
49. Virologic outcomes in early antiretroviral treatment: HPTN 052
- Author
-
Eshleman, Susan H., primary, Wilson, Ethan A., additional, Zhang, Xinyi C., additional, Ou, San-San, additional, Piwowar-Manning, Estelle, additional, Eron, Joseph J., additional, McCauley, Marybeth, additional, Gamble, Theresa, additional, Gallant, Joel E., additional, Hosseinipour, Mina C., additional, Kumarasamy, Nagalingeswaran, additional, Hakim, James G., additional, Kalonga, Ben, additional, Pilotto, Jose H., additional, Grinsztejn, Beatriz, additional, Godbole, Sheela V., additional, Chotirosniramit, Nuntisa, additional, Santos, Breno Riegel, additional, Shava, Emily, additional, Mills, Lisa A., additional, Panchia, Ravindre, additional, Mwelase, Noluthando, additional, Mayer, Kenneth H., additional, Chen, Ying Q., additional, Cohen, Myron S., additional, and Fogel, Jessica M., additional
- Published
- 2017
- Full Text
- View/download PDF
50. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
- Author
-
Godbole, Sheela V, Havlir, Diane, Eron, Joseph, Wang, Lei, Celentano, David, Nielsen-Saines, Karin, Hosseinipour, Mina C, Kumwenda, Johnstone, Piwowar-Manning, Estelle, Kumarasamy, Nagalingeshwaran, Mayer, Kenneth H, Essex, Max, Ribaudo, Heather J, Swindells, Susan, Chen, Ying Q, Eshleman, Susan H, Mills, Lisa A, Taha, Taha E, Pilotto, Jose H S, Gallant, Joel, Sanne, Ian, Chariyalertsak, Suwat, de Melo, Marineide Gonçalves, Hakim, James G, Panchia, Ravindre, Ou, San-San, McCauley, Marybeth, Anderson, Maija, Makhema, Joseph, Gamble, Theresa, Hoffman, Irving, and Grinsztejn, Beatriz
- Subjects
virus diseases - Abstract
Use of antiretroviral treatment for HIV-1 infection has decreased AIDS-related morbidity and mortality and prevents sexual transmission of HIV-1. However, the best time to initiate antiretroviral treatment to reduce progression of HIV-1 infection or non-AIDS clinical events is unknown. We reported previously that early antiretroviral treatment reduced HIV-1 transmission by 96%. We aimed to compare the effects of early and delayed initiation of antiretroviral treatment on clinical outcomes.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.